



HAL
open science

Thrombolysis and mechanical thrombectomy for acute ischemic stroke in octogenarian patients: a regional observational study

Manon Michelard

► **To cite this version:**

Manon Michelard. Thrombolysis and mechanical thrombectomy for acute ischemic stroke in octogenarian patients: a regional observational study. Human health and pathology. 2020. dumas-02966637

HAL Id: dumas-02966637

<https://dumas.ccsd.cnrs.fr/dumas-02966637v1>

Submitted on 14 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

AVERTISSEMENT

Ce document est le fruit d'un long travail approuvé par le jury de soutenance.

La propriété intellectuelle du document reste entièrement celle du ou des auteurs. Les utilisateurs doivent respecter le droit d'auteur selon la législation en vigueur, et sont soumis aux règles habituelles du bon usage, comme pour les publications sur papier : respect des travaux originaux, citation, interdiction du pillage intellectuel, etc.

Il est mis à disposition de toute personne intéressée par l'intermédiaire de [l'archive ouverte DUMAS](#) (Dépôt Universitaire de Mémoires Après Soutenance).

Si vous désirez contacter son ou ses auteurs, nous vous invitons à consulter la page de DUMAS présentant le document. Si l'auteur l'a autorisé, son adresse mail apparaîtra lorsque vous cliquerez sur le bouton « Détails » (à droite du nom).

Dans le cas contraire, vous pouvez consulter en ligne les annuaires de l'ordre des médecins, des pharmaciens et des sages-femmes.

Contact à la Bibliothèque universitaire de Médecine
Pharmacie de Grenoble :
bump-theses@univ-grenoble-alpes.fr

Année : 2020

**THROMBOLYSIS AND MECHANICAL THROMBECTOMY FOR ACUTE ISCHEMIC
STROKE IN OCTOGENARIAN PATIENTS: A REGIONAL OBSERVATIONAL
STUDY**

THÈSE
PRÉSENTÉE POUR L'OBTENTION DU TITRE DE DOCTEUR EN MÉDECINE
DIPLOME D'ÉTAT

Manon MICHELARD

[Données à caractère personnel]

THÈSE SOUTENUE PUBLIQUEMENT À LA FACULTÉ DE MÉDECINE DE GRENOBLE

Le : 09/10/2020

DEVANT LE JURY COMPOSÉ DE

Président du jury :

M. le Pr Olivier DETANTE

Membres :

M. le Pr Gaëtan GAVAZZI

M. le Pr Guillaume DEBATY

M. le Dr Jérémie PAPASSIN (directeur de thèse)

L'UFR de Médecine de Grenoble n'entend donner aucune approbation ni improbation aux opinions émises dans les thèses ; ces opinions sont considérées comme propres à leurs auteurs.

Doyen de la Faculté : Pr. Patrice MORAND

Année 2019-2020

ENSEIGNANTS DE L'UFR DE MEDECINE

CORPS	NOM-PRENOM	Discipline universitaire
PU-PH	ALBALADEJO Pierre	Anesthésiologie-réanimation et médecine péri-opératoire
PU-PH	APEL Florent	Ophthalmologie
PU-PH	ARVIEUX-BARTHELEMY Catherine	Chirurgie viscérale et digestive
PU-PH	BAILLET Athan	Rhumatologie
PU-PH	BARONE-ROCHETTE Gilles	Cardiologie
PU-PH	BAYAT Sam	Physiologie
MCF Ass.MG	BENDAMENE Farouk	Médecine Générale
PU-PH	BENHAMOU Pierre Yves	Endocrinologie, diabète et maladies métaboliques
PU-PH	BERGER François	Biologie cellulaire
MCU-PH	BIDART-COUTTON Marie	Biologie cellulaire
PU-PH	BLAISE Sophie	Chirurgie vasculaire ; médecine vasculaire
MCU-PH	BOISSET Sandrine	Bactériologie-virologie
PU-PH	BOLLA Michel	Cancérologie-Radiothérapie
PU-PH	BONAZ Bruno	Gastroentérologie, hépatologie, addictologie
PU-PH	BONNETERRE Vincent	Médecine et santé au travail
PU-PH	BOREL Anne-Laure	Nutrition
PU-PH	BOSSON Jean-Luc	Biostatistiques, informatique médicale et technologies de communication
MCU-PH	BOTTARI Serge	Biologie cellulaire
PR Ass.MG	BOUCHAUD Jacques	Médecine Générale
PU-PH	BOUGEROL Thierry	Psychiatrie d'adultes
PU-PH	BOUILLET Laurence	Médecine interne
MCU-PH	BOUSSAT Bastien	Epidémiologie, économie de la santé et prévention
PU-PH	BOUZAT Pierre	Anesthésiologie-réanimation et médecine péri-opératoire
PU-PH	BRAMBILLA Christian	Pneumologie
PU-PH	BRAMBILLA Elisabeth	Anatomie et cytologie pathologiques
MCU-PH	BRENIER-PINCHART Marie Pierre	Parasitologie et mycologie
PU-PH	BRICAULT Ivan	Radiologie et imagerie médicale
PU-PH	BRICHON Pierre-Yves	Chirurgie thoracique et cardiovasculaire
MCU-PH	BRIOT Raphaël	Thérapeutique-médecine de la douleur
MCU-PH	BROUILLET Sophie	Biologie et médecine du développement et de la reproduction
PU-PH	CAHN Jean-Yves	Hématologie
PU-PH	CARPENTIER Patrick	Chirurgie vasculaire, médecine vasculaire
PR Ass.MG	CARRILLO Yannick	Médecine Générale
PU-PH	CESBRON Jean-Yves	Immunologie
PU-PH	CHABARDES Stephan	Neurochirurgie
PU-PH	CHABRE Olivier	Endocrinologie, diabète et maladies métaboliques
PU-PH	CHAFFANJON Philippe	Anatomie

CORPS	NOM-PRENOM	Discipline universitaire
PU-PH	CHARLES Julie	Dermato-vénérologie
MCF Ass.MG	CHAUVET Marion	Médecine Générale
PU-PH	CHAVANON Olivier	Chirurgie thoracique et cardio- vasculaire
PU-PH	CHIQUET Christophe	Ophthalmologie
PU-PH	CHIRICA Mircea	Chirurgie viscérale et digestive
PU-PH	CINQUIN Philippe	Biostatistiques, informatique médicale et technologies de communication
MCU-PH	CLAVARINO Giovanna	Immunologie
PU-PH	COHEN Olivier	Histologie, embryologie et cytogénétique
PU-PH	COURVOISIER Aurélien	Chirurgie infantile
PU-PH	COUTTON Charles	Génétique
PU-PH	COUTURIER Pascal	Gériatrie et biologie du vieillissement
PU-PH	CRACOWSKI Jean-Luc	Pharmacologie fondamentale, pharmacologie clinique
PU-PH	CURE Hervé	Cancérologie
PU-PH	DEBATY Guillaume	Médecine d'Urgence
PU-PH	DEBILLON Thierry	Pédiatrie
PU-PH	DECAENS Thomas	Gastro-entérologie, Hépatologie
PU-PH	DEMATTEIS Maurice	Addictologie
PU-PH	DEMONGEOT Jacques	Biostatistiques, informatique médicale et technologies de communication
MCU-PH	DERANSART Colin	Physiologie
PU-PH	DESCOTES Jean-Luc	Urologie
PU-PH	DETANTE Olivier	Neurologie
MCU-PH	DIETERICH Klaus	Génétique
MCU-PH	DOUTRELEAU Stéphane	Physiologie
MCU-PH	DUMESTRE-PERARD Chantal	Immunologie
PU-PH	EPAULARD Olivier	Maladies infectieuses ; Maladies tropicales
PU-PH	ESTEVE François	Biophysique et médecine nucléaire
MCU-PH	EYSSERIC Hélène	Médecine légale et droit de la santé
PU-PH	FAUCHERON Jean-Luc	Chirurgie viscérale et digestive
MCU-PH	FAURE Julien	Biochimie et biologie moléculaire
PU-PH	FERRETTI Gilbert	Radiologie et imagerie médicale
PU-PH	FEUERSTEIN Claude	Physiologie
PU-PH	FONTAINE Éric	Nutrition
PU-PH	FRANCOIS Patrice	Epidémiologie, économie de la santé et prévention
MCU-MG	GABOREAU Yoann	Médecine Générale
PU-PH	GARBAN Frédéric	Hématologie ; Transfusion
PU-PH	GAUDIN Philippe	Rhumatologie
PU-PH	GAVAZZI Gaétan	Gériatrie et biologie du vieillissement
PU-PH	GAY Emmanuel	Neurochirurgie
MCU-PH	GILLOIS Pierre	Biostatistiques, informatique médicale et technologies de communication
PU-PH	GIOT Jean-Philippe	Chirurgie plastique, reconstructrice et esthétique
MCU-PH	GRAND Sylvie	Radiologie et imagerie médicale
PU-PH	GRIFFET Jacques	Chirurgie infantile
MCU-PH	GUZUN Rita	Nutrition
PU-PH	HAINAUT Pierre	Biochimie et biologie moléculaire
PU-PH	HALIMI Serge	Nutrition
PU-PH	HENNEBICQ Sylviane	Biologie et médecine du développement et de la reproduction
PU-PH	HOFFMANN Pascale	Gynécologie-obstétrique

CORPS	NOM-PRENOM	Discipline universitaire
PU-PH	HOMMEL Marc	Neurologie
PU-MG	IMBERT Patrick	Médecine Générale
PU-PH	JOUK Pierre-Simon	Génétique
PU-PH	KAHANE Philippe	Physiologie
MCU-PH	KASTLER Adrian	Radiologie et imagerie médicale
PU-PH	KRAINIK Alexandre	Radiologie et imagerie médicale
PU-PH	LABARERE José	Epidémiologie, économie de la santé et prévention
MCU-PH	LABLANCHE Sandrine	Endocrinologie, diabète et maladies métaboliques
MCU-PH	LANDELLE Caroline	Bactériologie – virologie ; Hygiène hospitalière
PU-PH	LANTUEJOU Sylvie	Anatomie et cytologie pathologiques
MCU-PH	LARDY Bernard	Biochimie et biologie moléculaire
MCU - PH	LE GOUELLEC Audrey	Biochimie et biologie moléculaire
PU-PH	LECCIA Marie-Thérèse	Dermato-vénérologie
MCF Ass.MG	LEDOUX Jean-Nicolas	Médecine Générale
PU-PH	LEROY Vincent	Gastroentérologie ; hépatologie ; addictologie
PU-PH	LETOUBLON Christian	Chirurgie viscérale et digestive
PU-PH	LEVY Patrick	Physiologie
PU-PH	LONG Jean-Alexandre	Urologie
MCU-PH	LUPO Julien	Bactériologie-virologie
PU-PH	MAGNE Jean-Luc	Chirurgie vasculaire ; Médecine vasculaire
MCU-PH	MAIGNAN Maxime	Médecine d'urgence
PU-PH	MAITRE Anne	Médecine et santé au travail
MCU-PH	MALLARET Marie-Reine	Hygiène hospitalière
PU-PH	MALLION Jean-Michel	Cardiologie
MCU-PH	MARLU Raphaël	Hématologie ; Transfusion
MCU-PH	MAUBON Danièle	Parasitologie et mycologie
PU-PH	MAURIN Max	Bactériologie-virologie
MCU-PH	MC LEER Anne	Histologie, embryologie et cytogénétique
MCU-PH	MONDET Julie	Histologie, embryologie et cytogénétique
PU-PH	MORAND Patrice	Bactériologie-virologie
PU-PH	MOREAU-GAUDRY Alexandre	Biostatistiques, informatique médicale et technologies de communication
PU-PH	MORO Elena	Neurologie
PU-PH	MORO-SIBILOT Denis	Pneumologie
MCU-PH	MORTAMET Guillaume	Pédiatrie
PU-PH	MOUSSEAU Mireille	Cancérologie
PU-PH	MOUTET François	Chirurgie plastique, reconstructrice et esthétique ; brûlologie
MCF Ass.MG	ODDOU Christel	Médecine Générale
MCU-PH	PACLET Marie-Hélène	Biochimie et biologie moléculaire
PU-PH	PAILHE Régis	Chirurgie orthopédique et traumatologie
PU-PH	PALOMBI Olivier	Anatomie
PU-PH	PARK Sophie	Hématologie ; Transfusion
PU-PH	PASSAGLIA Jean-Guy	Anatomie
PR Ass.MG	PAUMIER-DESBRIERES Françoise	Médecine Générale
PU-PH	PAYEN DE LA GARANDERIE Jean-François	Anesthésiologie-réanimation et médecine péri-opératoire
MCU-PH	PAYSANT François	Médecine légale et droit de la santé
MCU-PH	PELLETIER Laurent	Biologie cellulaire
PU-PH	PELLOUX Hervé	Parasitologie et mycologie

CORPS	NOM-PRENOM	Discipline universitaire
PU-PH	PEPIN Jean-Louis	Physiologie
PU-PH	PERENNOU Dominique	Médecine physique et de réadaptation
PU-PH	PERNOD Gilles	Médecine vasculaire
PU-PH	PIOLAT Christian	Chirurgie infantile
PU-PH	PISON Christophe	Pneumologie
PU-PH	PLANTAZ Dominique	Pédiatrie
PU-PH	POIGNARD Pascal	Bactériologie-virologie
PU-PH	POLACK Benoît	Hématologie
PU-PH	POLOSAN Mircea	Psychiatrie d'adultes
PU-PH	RAMBEAUD Jean-Jacques	Urologie
PU-PH	RAY Pierre	Biologie et médecine du développement et de la reproduction
MCU-PH	RENDU John	Biochimie et biologie moléculaire
MCU-PH	RIALLE Vincent	Biostatistiques, informatique médicale et technologies de communication
PU-PH	RIETHMULLER Didier	Gynécologie-obstétrique ; gynécologie médicale
PU-PH	RIGHINI Christian	Oto-rhino-laryngologie
PU-PH	ROMANET Jean Paul	Ophthalmologie
PU-PH	ROSTAING Lionel	Néphrologie
MCU-PH	ROUSTIT Matthieu	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie
MCU-PH	ROUX-BUISSON Nathalie	Biochimie et biologie moléculaire
MCF Ass.MG	ROYER DE VERICOURT Guillaume	Médecine Générale
MCU-PH	RUBIO Amandine	Pédiatrie
PU-PH	SARAGAGLIA Dominique	Chirurgie orthopédique et traumatologie
MCU-PH	SATRE Véronique	Génétique
PU-PH	SAUDOU Frédéric	Biologie cellulaire
PU-PH	SCHMERBER Sébastien	Oto-rhino-laryngologie
PU-PH	SCHWEBEL Carole	Médecine intensive-réanimation
PU-PH	SCOLAN Virginie	Médecine légale et droit de la santé
MCU-PH	SEIGNEURIN Arnaud	Epidémiologie, économie de la santé et prévention
PU-PH	STAHL Jean-Paul	Maladies infectieuses ; Maladies tropicales
PU-PH	STANKE Françoise	Pharmacologie fondamentale
MCU-PH	STASIA Marie-José	Biochimie et biologie moléculaire
PU-PH	STURM Nathalie	Anatomie et cytologie pathologiques
PU-PH	TAMISIER Renaud	Physiologie
PU-PH	TERZI Nicolas	Médecine intensive-réanimation
MCU-PH	TOFFART Anne-Claire	Pneumologie
PU-PH	TONETTI Jérôme	Chirurgie orthopédique et traumatologie
PU-PH	TOUSSAINT Bertrand	Biochimie et biologie moléculaire
PU-PH	VANZETTO Gérald	Cardiologie
PU-PH	VUILLEZ Jean-Philippe	Biophysique et médecine nucléaire
PU-PH	WEIL Georges	Epidémiologie, économie de la santé et prévention
PU-PH	ZAOUI Philippe	Néphrologie
PU-PH	ZARSKI Jean-Pierre	Gastroentérologie ; hépatologie ; addictologie

PU-PH : Professeur des Universités - Praticiens Hospitaliers
MCU-PH : Maître de Conférences des Universités - Praticiens Hospitaliers
PU-MG : Professeur des Universités de Médecine Générale
MCU-MG : Maître de Conférences des Universités de Médecine Générale
PR Ass.MG : Professeur des Universités Associé de Médecine Générale
MCF Ass.MG : Maître de Conférences Associé de Médecine Générale

REMERCIEMENTS

Je voudrais, dans un premier temps, remercier mon directeur de thèse le **Dr Jérémie Papassin** pour sa disponibilité (même entre deux vagues surfées en Bretagne), son enthousiasme lors de nos réunions (même entre deux avis téléphoniques) et surtout ses précieux conseils.

Je remercie également le **Pr Olivier Detante**, pour son enseignement durant mon passage à l'UNV puis son aide et ses conseils inestimables concernant ce travail.

Je tiens à témoigner toute ma reconnaissance au **Pr Gaëtan Gavazzi** et au **Pr Guillaume Debaty** qui me font l'honneur de juger ce travail.

Un grand merci à **Cécile Ricard** pour toute son aide à la réalisation de cette thèse concernant la partie statistique.

Je remercie du fond du cœur **mes parents** qui m'ont donné les moyens de pouvoir exercer ce métier grâce à leur soutien indéfectible, et m'ont toujours accompagnée et écoutée.

Je désire aussi remercier **ma famille** pour leurs encouragements.

Un grand merci à mon amoureux, **Arnaud**, pour son soutien, et particulièrement sa patience et sa détermination afin d'apaiser mes angoisses durant ce travail. Continuons à écrire cette histoire ensemble, qu'on aille « à droite, à gauche, en haut, en bas mais qu'on ne disparaisse pas ». Je t'aime.

J'aimerais remercier les personnes extraordinaires qui composent la promotion DESMU 2017-2021 : **Mélanie, Camille, Marion, Aurélie, Marine, Léa, Adèle, Amandine, Florentin, Briac, Quentin et Arthur**, pour les fou-rires, les soirées, les randos, l'escalade, le ski, la bière, la bonne humeur, la solidarité incroyable au sein de ce petit groupe.

Je désire aussi remercier les lyonnais, **Fanny, Claire, Jeanne, Marion, Lionel, Arnaud, Amélie, Caroline, Lucie, Lison** en souvenir d'un externat explosif.

J'adresse mes sincères remerciements à notre coordinateur de DES, le **Pr Maxime Maignan**, pour l'organisation de notre formation, son enseignement et son dévouement, ainsi qu'au **Dr Damien Viglino**.

J'aimerais exprimer ma gratitude à tous les **médecins, infirmiers, aide-soignants** (je ne peux tous les nommer) rencontrés durant ces années, qui m'ont formée et m'ont tant appris.

Je remercie tous mes **co-internes** pour les très bons moments partagés ensemble et leur soutien dans les moments les plus difficiles.

A tous mes amis, un grand merci, **Elise, Gaëlle, Kévin...** et tant d'autres que j'oublie (et je m'en excuse par avance...).

ABSTRACT

Introduction: Elderly patients represent a growing stroke population characterized by a higher frailty, underrepresented in clinical trials. We investigated safety, efficacy and prognosis factors of intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) in elderlies.

Methods: We conducted a retrospective analysis of acute ischemic stroke patients hospitalized in the 4 Stroke Units of the French Northern Alps Emergency Network (RENAU-AVC) between 2014 and 2019. We compared clinical characteristics, functional outcome and mortality between ≥ 80 years old (yo), < 80 yo patients, and subgroup of nonagenarians (≥ 90 yo).

Results: Number of ≥ 80 yo patients admitted has doubled in 6 years with a 5-fold increase of IVT and/or MT (30 procedures in 2014 vs 173 in 2019). After IVT and/or MT, ≥ 80 yo patients had a poorer functional outcome at discharge (modified Rankin scale 0 to 2 = 34.1% vs 60.8%) and at 6 months (18.1% vs 43.1%). Mortality rate was higher in ≥ 80 yo compared to < 80 yo patients (21.1% vs 5.6%). For patients undergoing IVT and/or MT, age over 80 years and high initial NIHSS (National Institute of Health Stroke Scale) were poor prognosis factors. Interestingly, no difference was observed for functional independence or mortality between octogenarians (≥ 80 yo) and nonagenarians (≥ 90 yo).

Discussion: IVT and MT in AIS management are feasible in octogenarians and nonagenarians but functional outcome remains poor compared to younger patients. Studies including elderlies are needed to better select patients that would benefit from IVT and/or MT.

Keywords: ischemic stroke, octogenarians, nonagenarians, intravenous thrombolysis, mechanical thrombectomy, outcome

TABLE OF CONTENTS

LIST OF ABBREVIATIONS

INTRODUCTION

METHODS

- 1) Patient selection
- 2) Data collection
- 3) Recanalization procedures
- 4) Outcomes
- 5) Statistical analysis

RESULTS

- 1) Number of ischemic strokes and recanalization attempts evolution in the French Northern Alps Emergency Network (RENAU-AVC)
- 2) Characteristics of overall patients with AIS
- 3) Characteristics of patients with AIS and undergoing a recanalization attempt
- 4) Functional outcomes
- 5) Prognosis factors

DISCUSSION

- 1) Epidemiology: increasing of number of elderly patients in stroke units
- 2) Safety and efficacy of recanalization strategies
- 3) Prognosis factors in elderly stroke patients
 - a. Age
 - b. Delays
 - c. Successful of recanalization
 - d. NIHSS score initial
- 4) Pre-stroke disability in elderly
- 5) Selection patient
- 6) Limitations

CONCLUSION

BIBLIOGRAPHY

LIST OF ABBREVIATIONS

IVT: intravenous thrombolysis

MT: mechanical thrombectomy

RCTs: randomized clinical trials

AIS: acute ischemic stroke

LVO: large vessel occlusion

NIHSS: National Institute of Health Stroke Scale

MRI: Magnetic Resonance Imaging

CT: Computerized Tomography

mTICI: modified Thrombolysis In Cerebral Ischemia

mRS: modified Rankin Scale

med: median

IQR: interquartile range

CI: confidence interval

OR: odd ratio

yo: years old

ref: reference

INTRODUCTION

About one-third of stroke occurred in subjects over 80 years and 17% in those over 85 years (1). A result of ageing and growth of the population, the burden of cardioneurovascular disease will substantially increase. Due to improvement in health care and better standards of living, the number of stroke events is also expected to more than double (2) by the year 2050, with the majority of the increase among the elderly (3). As one of the fastest growing portions of the population, octogenarians will constitute a significant percentage of the stroke patient population in the near future. Octogenarians are nevertheless not specifically targeted by most clinical guidelines. Elderly were often excluded or under-represented in randomized clinical trials (RCTs).

When delivered within 4.5 hours, intravenous thrombolysis (IVT) significantly improves the overall odds of a good stroke outcome. Proportional treatment benefits were similar irrespective of age or stroke severity (4). In most European countries in 2014, IVT is also restricted to patients younger than 80 years but this meta-analysis shows the effect of Alteplase treatment was similar for patients aged 80 years or younger.

Mechanical thrombectomy (MT) trials that included elderly patients (over 80 years) showed better outcomes when treated with IVT+MT (“bridging therapy”) compared to IVT alone, with more favorable odds ratios than among younger patients (5).

However, the efficacy of IVT+MT for acute ischemic stroke in octogenarians is still controversial. Recent studies have reported higher morbidity and mortality in elderly patients than in their younger counterparts (6–9).

We aim to describe ageing and growth evolution of population in Northern French Alps Stroke Units (RENAU-AVC network) and investigate safety, efficacy and prognosis factors of IVT and/or MT in octogenarians and nonagenarians.

METHODS

1) Patient selection

All consecutive patients referred to the 4 Stroke Units of Northern French Alps (Annecy, Annemasse, Chambéry, Grenoble) for acute ischemic stroke (AIS) between January 2014 and December 2019 were prospectively included in the registry. Ischemic stroke was diagnosed by a stroke neurologist based on clinical and imaging data.

2) Data collection

Clinical and radiological baseline data, including age, sex, large vessel occlusion (LVO), wake-up stroke, National Institute of Health Stroke Scale (NIHSS) score at presentation, brain imaging type, etiology of stroke, management delays (door-to-imagery, door-to-needle, door-to-puncture (for MT), door-to-recanalization), in-hospital mortality and functional outcomes were collected from medical records by a trained physician. Quality controls were performed before analysis.

3) Recanalization procedures

All IVT were administered at dose of 0.9mg/kg Alteplase and MT was performed using contact aspiration and/or stent retriever. Modified Thrombolysis In Cerebral Ischemia (mTICI; 0 to 3) recanalization grading scores were collected. Successful recanalization was defined as a mTICI score ≥ 2 .

4) Outcomes

A clinical assessment was realized at discharge and between three and six months post-stroke by a neurologist. Functional outcome was assessed using the modified Rankin Scale (mRS), ranged from 0 (no symptom) to 6 (death). Favorable outcome is defined as mRS 0-2 (i.e. alive and independent) and poor outcome is defined as mRS 3-6. We divided the patients into age

groups for analysis. Firstly, we compared younger patients <80 years old (<80yo) and elderly patients ≥ 80 yo and secondly, we compared octogenarians (80-89yo) with nonagenarians (≥ 90 yo).

5) Statistical analysis

Continuous variables were presented as the mean \pm standard deviation or median and interquartile range (IQR) with 25th and 75th percentiles and compared with the Student's t-test or Mann-Whitney U test. The assessment different variables to predict good or poor outcomes after recanalization procedure in elderly patients compared with younger adults used multivariate stepwise logistic regression. SPSS version 26.0 was used for all statistical analysis.

RESULTS

1) Number of ischemic strokes and recanalization attempts evolution in the French Northern Alps Emergency Network (RENAU-AVC)

The number of AIS patients over the age of 80 years in stroke units increased from 225 (24% of patients) in 2014 to 500 (35% of patients) in 2019. Indeed, proportion of 80-89yo increased about of 222% and proportion of ≥ 90 yo increased about of 324% during the same period. (Table 1)

Number of recanalization attempts also dramatically increased (Table 1 and Figure 1) with 137 recanalization attempts for <80 yo patients in 2014 *versus* 268 in 2019, 28 for 80-89yo patients *versus* 136 in 2019, and 2 for ≥ 90 yo in 2014 *versus* 37 in 2019. Number of MT 4-fold increased between 2015 (n = 26) and 2016 (n = 110) among all patients hospitalized for AIS in stroke units with the rise of MT during the year 2015 and continue to increase (n = 191 in 2019), especially in octogenarians (n = 3 in 2015 and n = 69 in 2019) and nonagenarians (n = 1 in 2015 and n = 12 in 2019).

		2014	2015	2016	2017	2018	2019
<80yo	AIS	699	859	957	915	1018	936
	Reca	137	166	210	237	266	268
	- IVT	125	144	135	144	148	158
	- MT/B	12	22	75	93	118	110
80-89yo	AIS	192	287	360	374	424	393
	Reca	28	62	82	107	128	136
	- IVT	28	59	50	65	69	67
	- MT/B	0	3	32	42	59	69
≥90yo	AIS	33	66	75	80	105	107
	Reca	2	7	20	20	29	37
	- IVT	2	6	17	17	21	25
	- MT/B	0	1	3	3	8	12
Overall	AIS	924	1212	1392	1369	1547	1436
	Reca	167	235	312	364	423	441
	- IVT	155	209	202	226	238	250
	- MT/B	12	26	110	138	185	191

yo: years old

Table 1: Number of acute ischemic stroke (AIS) patients admitted in Northern French Alps stroke units and number of recanalization attempts (Reca) with number of Intravenous Thrombolysis alone (IVT) and Mechanical Thrombectomy alone or Bridging (MT/B) by age groups between 2014 and 2019.




Figure 1: Evolution of annual number of recanalization attempts by age group between 2014 and 2019

2) Characteristics of overall patients with AIS

In this cohort of 7880 AIS patients, 5384 are <80yo, 2496 are ≥80yo of which 466 are ≥90yo. Patients ≥80yo were more female and had more severe strokes compared with <80yo (median NIHSS = 7 [3 – 15] vs 4 [1 – 8], p < 0.001). Nonagenarians were more female compared with octogenarians and had more severe strokes (median NIHSS = 8 [3.75 – 18] vs 6 [2 – 14], p < 0.001). The baseline characteristics are summarized in Table 2.

	<80yo (n=5384)	≥80yo (n=2496)	p values	80-89yo (n=2030)	≥90yo (n=466)	p values
Men (n, %)	3542 (65.8%)	1086 (43.5%)	< 0.001	933 (46.0%)	153 (32.8%)	< 0.001
Age (med, IQR)	66 [56 - 73]	85 [82 – 88]	< 0.001	84 [82 – 86]	92 [91 – 94]	< 0.001
NIHSS scale at presentation (med, IQR)	4 [1 – 8]	7 [3 – 15]	< 0.001	6 [2 – 14]	8 [3.75 – 18]	0.001
NIHSS ≤ 5 (n, %)	3256 (60.5%)	1060 (42.5%)		899 (44.3%)	161 (34.5%)	
NIHSS 6-10 (n, %)	832 (15.5%)	483 (19.4%)		393 (19.4%)	90 (19.3%)	
NIHSS 11-15 (n, %)	423 (7.9%)	269 (10.8%)		213 (10.5%)	56 (12.0%)	
NIHSS 16-20 (n, %)	344 (6.4%)	266 (10.7%)		201 (9.9%)	65 (13.9%)	
NIHSS > 20 (n, %)	273 (5.1%)	296 (11.9%)		226 (11.1%)	70 (15.0%)	
LVO (n, %)	1045 (19.4%)	598 (24.0%)	< 0.001	491 (24.2%)	107 (23.0%)	0.600
MRI (n, %)	2016 (37.4%)	765 (30.6%)	< 0.001	662 (32.6%)	103 (22.1%)	< 0.001
Wake up stroke (n, %)	321 (6.0%)	147 (5.9%)	0.900	119 (6.3%)	28 (6.6%)	0.800
Recanalization attempt (n, %)	1284 (23.8%)	658 (26.4%)	0.030	543 (26.7%)	115 (24.7%)	0.300

IQR = interquartile range; IVT = intravenous thrombolysis; LVO = large vessel occlusion; NIHSS = National Institute of Health Stroke Scale; MRI = Magnetic Resonance Imaging; med = median; IQR = interquartile range; yo = years old

Table 2: Characteristics baseline of overall patients with acute ischemic stroke (AIS)

3) Characteristics of patients with AIS and undergoing a recanalization attempt

In this cohort of 7880 AIS patients, 1942 underwent a recanalization attempt (IVT alone or MT alone or bridging), 658 patients (33.9%) were ≥ 80 yo. The baseline characteristics are summarized in Table 3.

Patients ≥ 80 yo are more female (60.0% vs 37.7%, $p < 0.001$) and have more severe ischemic strokes (median NIHSS = 13[8 - 20] vs 9 [5 - 16,75], $p < 0.001$) than younger patients (< 80 yo). Patients ≥ 80 yo have significantly more LVO (60% vs 50.5%, $p < 0.001$) and more cardioembolic etiology stroke (52.5% vs 33.2%, $p < 0.001$) than < 80 yo. There were no significant difference concerning recanalization strategies between both groups: 64.7% vs 66.5% for IVT alone, 13.4% vs 12.9% for MT alone and 21.9% vs 20.6% for bridging (IVT+MT), $p = 0.700$. Proportion of patients receiving MRI rather than CT was not different between groups. Proportion of successful recanalization was not different between both groups (61.6% of ≥ 80 yo vs 67.2% for < 80 yo, $p = 0.060$). Onset-to-treatment delay was not different between both groups (180 min for both, $p = 0.630$). Door-to-treatment time was significantly longer for ≥ 80 yo (80 min vs 73 min, $p = 0.001$).

We compared 543 octogenarians with 115 nonagenarians who underwent a recanalization attempt. Nonagenarians were more female (67.0% vs 58.6%, $p < 0.001$) and had more severe strokes (median NIHSS = 17 [9 - 21] vs 13 [7 - 20], $p < 0.001$) with more LVO. Nonagenarians had even more cardioembolic etiology stroke than octogenarians (58.8% vs 51.4% respectively, $p < 0.001$). Proportion of patients receiving MRI rather than CT was not different between both groups. There were more IVT alone (76.5% vs 62.2%) and less bridging (10.4% vs 24.3%) in the ≥ 90 yo group compared with octogenarians. The rate of successful recanalization was comparable between nonagenarians and octogenarians (59.3% vs 62.0%, $p = 0.400$).

Onset-to-treatment time are not different between both groups (180 min vs 179 min, $p = 0.820$).

Door-to-treatment time is significantly longer for nonagenarians (81 min vs 78 min, $p = 0.001$).

	<80yo (n=1284)	≥80yo (n=658)	p values	80-89yo (n=543)	≥90yo (n=115)	p values	
Men (n, %)	800 (62.3%)	263 (40.0%)	< 0.001	225 (41.4%)	38 (33.0%)	< 0.001	
Age (med, [IQR])	67 [56 – 74]	85 [82 – 88]	< 0.001	84 [82 – 86]	92 [90 – 94]	< 0.001	
NIHSS at presentation (med, [IQR])	9 [5 – 16,75]	13 [8 - 20]	< 0.001	13 [7 - 20]	17 [9 - 21]	< 0.001	
NIHSS ≤ 5 (n, %)	365 (28.4%)	93 (14.1%)		84 (15.5%)	9 (7.8%)		
NIHSS 6-10 (n, %)	317 (24.7%)	150 (22.8%)		121 (22.3%)	29 (25.2%)		
NIHSS 11-15 (n, %)	221 (17.2%)	123 (18.7%)		104 (19.2%)	19 (16.5%)		
NIHSS 16-20 (n, %)	183 (14.7%)	136 (21.1%)		112 (21.2%)	24 (20.9%)		
NIHSS > 20 (n, %)	158 (12.7%)	142 (22.0%)		108 (20.4%)	34 (29.6%)		
LVO (n, %)	649 (50.5%)	395 (60.0%)	< 0.001	324 (59.7%)	71 (61.7%)	< 0.001	
MRI (n, %)	852 (66.4%)	410 (62.3%)	0.077	343 (63.2%)	67 (58.3%)	0.130	
Wake up stroke (n, %)	41 (3.2%)	13 (2.0%)	0.100	10 (1.8%)	3 (2.6%)	0.600	
Recanalization type strategy (n, %)	IVT alone	854 (66.5%)	426 (64.7%)	338 (62.2%)	88 (76.5%)	0.020	
	MT alone	165 (12.9%)	88 (13.4%)	73 (13.4%)	15 (13.0%)		
	IVT + MT	265 (20.6%)	144 (21.9%)	132 (24.3%)	12 (10.4%)		
Etiology (n, %)	Atheroma	210 (27.3%)	83 (24.5%)	74 (25.7%)	9 (17.6%)	< 0.001	
	Cardio-embolic	256 (33.2%)	178 (52.5%)	148 (51.4%)	30 (58.8%)		
	Others	304 (39.5%)	78 (23.0%)	63 (21.9%)	11 (21.6%)		
Delays (med, [IQR])	Door to imagery	35 [22 - 54]	39 [24 - 59]	0,009	38 [23 – 58]	43 [27 – 70]	0.003
	Door to needle	71 [55 – 93]	76 [59 – 101]	0.002	75.5 [59 – 101]	78 [62 – 110]	0.005
	Door to puncture for MT only	129 [84 – 197]	137 [105 – 192]	0.180	135 [102 – 193]	144 [120 – 173]	0.330
	Door to treatment	73 [55 – 98]	80 [60- 110]	0.001	78 [59 – 108]	81 [64 – 221]	0.001
	Door to recanalization for MT only	170 [126.5 – 134.5]	182 [145 – 216.5]	0.274	182 [140 – 117]	183.5 [180 – 204]	0.430
	Onset to treatment	180 [144.8 – 231.3]	180 [144.3 – 220]	0.630	180 [145 – 221]	179 [139.3 – 210]	0.820
	Onset to door	98 [67 – 151]	90 [64.25 – 135.75]	0.010	93 [65 – 140]	81 [60 – 117]	0.400
mTICI score (n, %)	mTICI ≤ 2a	73 (17.0%)	57 (24.6%)	0.060	48 (23.4%)	9 (33.3%)	0.400
	mTICI ≥ 2b	289 (67.2%)	143 (61.6%)	127 (62.0%)	16 (59.3%)		
	TICI missing	68 (15.8%)	32 (13.8%)	30 (14.6%)	2 (7.4%)		

IQR = interquartile range; IVT = intravenous thrombolysis; MT = mechanical thrombectomy; LVO = large vessel occlusion; NIHSS score = National Institute of Health Stroke score; MRI = Magnetic Resonance Imaging; med = median; IQR = interquartile range; mTICI: modified Thrombolysis In Cerebral Ischemia; yo = years old.

Table 3: Characteristics of patients with acute ischemic stroke (AIS) and undergoing a recanalization attempt

4) Functional outcomes

Whatever recanalization strategies (IVT alone, MT alone or bridging), ≥ 80 yo had significantly lower rate of good outcome at discharge (mRS 0-2 = 34.1% vs 60.8%; $p < 0.001$) compared with < 80 yo. In-hospital mortality was significantly higher in ≥ 80 yo group (21.1% vs 5.6%, $p < 0.001$). There is no significant difference between nonagenarians and octogenarians for good functional outcome rate at discharge (27.7% vs 35.5% respectively, $p = 0.100$). In-hospital mortality have a non-significant trend to be higher for nonagenarians compared to octogenarians (27% vs 19.9%; $p = 0.090$). (Table 4, Figures 2 and 4)

≥ 80 yo patients had also a lower rate of good outcome after 3-6 months compared with < 80 yo patients (18.1% vs 43.1%; $p < 0.001$), whatever recanalization strategies. There is no significant difference between nonagenarians and octogenarians for good functional outcome at 3-6 months (17.4% vs 18.2%, $p = 0.800$). (Table 4, Figures 3 and 5)

Younger (< 80 yo) patients have significantly better rates of good outcome (mRS 0-2) at discharge, whatever for IVT (68.7% vs 39.3%, $p < 0.001$) or MT/bridging (45.1% vs 24.7%, $p < 0.001$) compared with the ≥ 80 yo patients. We found same results at 3-6 months, whatever for IVT (49.1% vs 21.4%, $p < 0.001$) or MT/bridging (31.4% vs 12.1%, $p < 0.001$). (Table 4)

Octogenarians had not better rates of good outcome (mRS 0-2) at discharge compared to nonagenarians, whatever for IVT (41.6% vs 30.6%, $p = 0.100$) or MT/bridging (25.5% vs 18.5%, $p = 0.400$). Results were the same at 3-6 months, whatever for IVT (21.9% vs 19.3%, $p = 0.600$) or MT/bridging (12.2% vs 11.8%, $p = 0.900$). (Table 4)

		< 80yo (n=1284)	≥ 80yo (n=658)	p values	80-89yo (n=543)	≥ 90yo (n=115)	p values
In hospital mortality (n, %)		72 (5.6%)	139 (21.1%)	< 0.001	108 (19.9%)	31 (27.0%)	0.090
mRS 0-2 at discharge	IVT (n, %)	549 (68.7%)	162 (39.3%)	< 0.001	136 (41.6%)	26 (30.6%)	0.100
	MT/B (n, %)	181 (45.1%)	56 (24.7%)	< 0.001	51 (25.5%)	5 (18.5%)	0.400
	Overall (n, %)	730 (60.8%)	218 (34.1%)	< 0.001	187 (35.5%)	31 (27.7%)	0.100
mRS 0-2 at 3-6 months	IVT (n, %)	419 (49.1%)	91 (21.4%)	< 0.001	74 (21.9%)	17 (19.3%)	0.600
	MT/B (n, %)	135 (31.4%)	28 (12.1%)	< 0.001	25 (12.2%)	3 (11.8%)	0.900
	Overall (n, %)	554 (43.1%)	119 (18.1%)	< 0.001	99 (18.2%)	20 (17.4%)	0.800

mRS = modified Rankin Scale; yo = years old

Table 4: Functional outcome after recanalization attempt by Intravenous Thrombolysis alone (IVT) and Mechanical Thrombectomy alone or Bridging (MT/B)




Figure 2: Distribution of modified Rankin Scale (mRS) scores at discharge after a recanalization attempt between patients aged < 80 years old and ≥ 80 years old




Figure 3: Distribution of modified Rankin Scale (mRS) scores at 3-6 months after a recanalization attempt between patients aged < 80 years old and ≥ 80 years old




Figure 4: Distribution of modified Rankin Scale (mRS) scores at discharge after a recanalization attempt between octogenarians and nonagenarians




Figure 5: Distribution of modified Rankin Scale (mRS) scores at 3-6 months after a recanalization attempt between octogenarians and nonagenarians

5) Prognosis factors of poor outcomes after recanalization attempt

Regarding all acute ischemic stroke patients hospitalized in stroke units, recanalization attempts were associated with lower odds of poor outcome (mRS 3-6) at discharge for <80yo (OR 0.624, CI (0.497-0.785), $p < 0.001$) and ≥ 80 yo (OR 0.664, CI (0.495-0.890), $p < 0.006$). Higher admission NIHSS was a significant predictor of poor outcome (mRS 3-6) at discharge for the both groups. Onset-to-door delay is not significant. (Table 5)

	<80yo (n=5384)			≥ 80 yo (n=2496)		
	OR	CI 95%	p value	OR	CI 95%	p value
Recanalization attempt	0.624	0.497 – 0.785	< 0.001	0.664	0.495 – 0.890	0.006
NIHSS ≤ 5 (ref)			< 0.001			< 0.001
NIHSS 6-10	4.651	3.629 – 5.961	< 0.001	3.828	2.773 – 5.283	< 0.001
NIHSS 11-15	12.486	9.132 – 17.072	< 0.001	7.458	4.999 – 11.126	< 0.001
NIHSS 16-20	30.594	22.324 – 41.928	< 0.001	23.152	15.186 – 35.297	< 0.001
NIHSS > 20	40.202	17.818 – 90.706	< 0.001	27.024	11.156 – 65.460	< 0.001
Onset-to-door > 90 min	1.446	1.166 – 1.794	0.001	1.079	0.823 – 1.415	0.581

NIHSS = National Institute of Health Stroke Scale; OR = odd ratio, CI = confidence interval; ref = reference

Table 5: Multivariate analysis for predictors of poor outcome at discharge by age group in all acute ischemic stroke patients and hospitalized in stroke units

An age of ≥ 80 years old was associated with higher odds of poor outcome at discharge in patients undergoing IVT (OR=2.601, CI (1.933 – 3.501), $p < 0.001$) and patients undergoing MT or bridging (OR=3.439, CI (1.847 – 6.407), $p < 0.001$) independently. Higher admission NIHSS is a significant predictor of poor outcome for the both groups. Delays (onset-to-door > 90 min, door-to-IVT > 60 min, door-to-puncture > 120 min) were not significant. (Table 6)

	IVT			MT alone or bridging		
	OR	CI 95%	p value	OR	CI 95%	p value
Age ≥ 80 yo	2.601	1.933 – 3.501	< 0.001	3.439	1.847 – 6.407	< 0.001
NIHSS ≤ 5 (ref)			< 0.001			0.012
NIHSS 6-10	2.127	1.475 – 3.067	< 0.001	1.367	0.369 – 5.066	0.640
NIHSS 11-15	4.302	2.817 – 6.568	< 0.001	1.618	0.510 – 5.139	0.414
NIHSS 16-20	9.287	5.622 – 15.341	< 0.001	3.632	1.203 – 10.960	0.022
NIHSS > 20	29.137	14.859 – 57.135	< 0.001	4.355	1.403 – 13.518	0.011
Onset-to-door > 90 min	1.348	1.004 – 1.811	0.047	1.711	0.944 – 3.102	0.077
Door-to-needle > 60 min	1.014	0.733 – 1.404	0.932	1.061	0.565 – 1.993	0.854
Door-to-puncture > 120 min (for MT)				1.216	0.637 – 2.321	0.553

IVT = intravenous thrombolysis; MT = mechanical thrombectomy; NIHSS = National Institute of Health Stroke Scale; OR = odd ratio, CI = confidence interval; ref = reference

Table 6: Multivariate analysis for predictors of poor outcome (mRS 3-6) at discharge after recanalization attempt by recanalization strategy

An age of ≥ 80 years old was associated with higher odds of poor outcome at 3-6 months in patients undergoing IVT (OR=2.950, CI (2.174 – 4.004), $p < 0.001$) and patients undergoing MT or bridging (OR=3.242, CI (1.622 – 6.481), $p < 0.001$) independently. Higher admission NIHSS was a significant predictor of poor outcome for the both groups. Time of door-to-puncture > 120 min was significantly associated with odds of poor outcome (OR = 3.320, CI (1.657 – 6.653), $p < 0.001$). (Table 7)

	IVT			MT alone or bridging		
	OR	CI 95%	p value	OR	CI 95%	p value
Age ≥ 80 yo	2.950	2.174 – 4.004	< 0.001	3.242	1.622 – 6.481	0.001
NIHSS ≤ 5 (ref)			< 0.001			0.037
NIHSS 6-10	1.286	0.940 – 1.760	0.116	2.267	0.594 – 8.657	0.231
NIHSS 11-15	1.933	1.297 – 2.880	0.001	1.604	0.508 – 5.060	0.420
NIHSS 16-20	3.556	2.129 – 5.938	< 0.001	4.025	1.305 – 12.416	0.015
NIHSS > 20	10.778	5.028 – 23.106	< 0.001	4.245	1.333 – 13.520	0.014
Onset-to-door > 90 min	1.073	0.817 – 1.409	0.613	1.268	0.673 – 2.389	0.463
Door-to-needle > 60 min	1.022	0.755 – 1.382	0.889	0.517	0.259 – 1.034	0.062
Door-to-puncture > 120 min (for MT)				3.320	1.657 – 6.653	0.001

Abbreviations are defined in Table 6.

Table 7: Multivariate analysis for predictors of poor outcome (mRS 3-6) at 3-6 months after recanalization attempt by recanalization strategy

Etiology and delays (onset-to-door, door-to-needle, door-to-puncture) were not associated with higher risk of poor outcome in elderly (≥ 80 yo) undergoing a recanalization attempt (Table 8, 9 and 10). Higher admission NIHSS was a significant predictor of poor outcome (Table 8 and 9). For elderly (≥ 80 yo) patients undergoing MT or bridging, TICI $\geq 2b$ was significantly associated with lower odd of poor outcome (OR = 0.149, CI (0.074 – 0.302), $p < 0.001$). (Table 10)

	≥ 80 yo with recanalization attempt		
	OR	CI 95%	p value
NIHSS ≤ 5 (ref)			< 0.001
NIHSS 6-10	2.078	0.892 – 4.839	0.090
NIHSS 11-15	3.186	1.329 – 7.639	0.009
NIHSS 16-20	13.565	5.272 – 34.902	< 0.001
NIHSS > 20	14.034	5.522 – 35.663	< 0.001
Etiology = atheroma (ref)			0.387
Etiology = cardio-embolic	0.914	0.488 – 1.712	0.779
Etiology = others	1.474	0.684 – 3.177	0.322
Onset-to-door > 90 min	1.497	0.880 – 2.545	0.137

NIHSS = National Institute of Health Stroke Scale; OR = odd ratio; CI = confidence interval; ref = reference; yo = years old.

Table 8: Multivariate analysis for predictors of poor outcome at discharge after recanalization attempt for ≥ 80 yo patients

	≥ 80 yo with IVT		
	OR	CI 95%	p value
NIHSS ≤ 5 (ref)			< 0.001
NIHSS 6-10	2.420	0.951 – 6.160	0.064
NIHSS 11-15	3.105	1.178 – 8.189	0.022
NIHSS 16-20	13.464	4.503 – 40.259	< 0.001
NIHSS > 20	20.071	5.990 – 67.254	< 0.001
Onset-to-door > 90 min	1.208	0.637 – 2.291	0.563
Door-to-needle > 60 min	0.792	0.376 – 1.672	0.542
Etiology = atheroma (ref)			0.394
Etiology = cardio-embolic	0.826	0.401 – 1.700	0.604
Etiology = others	1.456	0.602 – 3.523	0.404

IVT = intravenous thrombolysis; MT = mechanical thrombectomy; NIHSS = National Institute of Health Stroke Scale; OR = odd ratio, CI = confidence interval; mTICI = modified Thrombolysis In Cerebral Ischemia; ref = reference; yo = years old.

Table 9: Multivariate analysis for predictors of poor outcome at discharge after IVT for ≥ 80 yo patients

	≥ 80yo with MT alone or bridging		
	OR	CI 95%	p value
NIHSS ≤ 5 (ref)			< 0.033
NIHSS 6-10	0.493	0.066 – 3.705	0.492
NIHSS 11-15	0.943	0.145 – 6.120	0.951
NIHSS 16-20	3.170	0.532 – 18.906	0.205
NIHSS > 20	4.213	0.662 – 26.831	0.128
Onset-to-door > 90 min	0.743	0.299 – 1.848	0.523
Door-to-puncture > 120 min	1.452	0.471 – 4.475	0.516
TICI ≥ 2b	0.149	0.074 – 0.302	< 0.001

IVT = intravenous thrombolysis; MT = mechanical thrombectomy; NIHSS = National Institute of Health Stroke Scale; OR = odd ratio, CI = confidence interval; mTICI = modified Thrombolysis In Cerebral Ischemia; ref = reference; yo = years old

Table 10: Multivariate analysis for predictors of poor outcome at discharge after MT alone or bridging for ≥ 80yo patients

DISCUSSION

We demonstrated the sharp increase of number of octogenarian and nonagenarian patients together with the large increase of number of IVT and MT in Northern French Alps stroke units between 2014 and 2019. IVT and MT are feasible procedures in elderlies (≥ 80 yo) but older are worse prognostic than younger (< 80 yo) with higher mortality in-hospital and lower good outcome (mRS 0-2) at discharge and at 3-6 months after stroke. Door-to-treatment (including door-to-needle and door-to-puncture) is significantly longer in elderly people.

In our “in-hospital” cohort, AIS in elderly are more severe with more LVO which could explain higher mortality and disability. Interestingly, there is not significant difference between octogenarian and nonagenarian groups. There seems to be some kind of “cut-off” limited to 80 years old. Multivariate analysis showed recanalization procedures in elderly are beneficial to patients with severe stroke with high NIHSS (Table 8). Speed of patient management with door-to-puncture delay is necessary to improve functional outcome (Table 7). Successful of recanalization (mTICI ≥ 2 b) was significantly associated with better outcome (Table 10). Etiology of AIS has no significant effect in our study (Table 8 and 9).

1) Epidemiology: increasing of number of elderly patients in stroke units

Since few years in Northern French Alps stroke units, number of IVT and MT had increased over than expected (10), particularly in elderly population because of aging, growth of the population and improvement in health care (3). The number of patients ≥ 80 yo admitted to stroke unit has doubled in 6 years, with a 5-fold increase of recanalization procedures. Number of AIS nonagenarians in stroke units has tripled. With the rise of MT during the year 2015 after pivotal RCTs (11–16), number of annual MT has quadrupled between 2015 ($n = 26$) and 2016 ($n = 110$) and continue to increase ($n = 191$ in 2019) among all patients hospitalized for AIS in stroke units, especially for ≥ 80 yo patients ($n = 4$ in 2015 and $n = 81$ in 2019). More and more elderly

patients are admitted (3) for stroke and the adaptation of the means dedicated to the whole health network (emergency unit, stroke unit beds, geriatric stroke unit, neurorehabilitation unit) is necessary in order to receive and care the greatest number of patients whatever their age.

Elderly patients were underrepresented in RCTs. They are undergoing a kind of “discrimination” according to some studies (17,18). Patients ≥ 80 yo and with preexisting disabilities had a lower chance of being treated with IVT whereas disabilities were not a contraindication (19). In our study, imaging or recanalization strategies were not statistically different between groups but there is a significant difference for delays between < 80 yo and ≥ 80 yo.

Our study shows an increasing incidence of atrial fibrillation in the elderly population compared to younger. This increasing incidence of atrial fibrillation is expected to increase the number of AIS caused by LVO and stroke severity in this population (20,21).

2) Safety and efficacy of recanalization strategies

In our cohort, recanalization attempts are associated with lower odds of poor outcome at discharge for < 80 yo and ≥ 80 yo. The rates of successful recanalization were not statistically different between groups. These findings suggest age should not be a contraindication because of age alone. Door-to-treatment delay was significantly longer for older groups but few minutes in practice. IVT and MT are feasible for elderly. Some studies have reported a higher likelihood of arterial tortuosity which may prolong the time to successful recanalization by MT. Aging would promote twisting of arteries and may make catheter access more time-consuming (22). However, several studies found no age-related difference in recanalization rate, procedural time, and complication rate in MT between elderly (≥ 80 yo) and younger people (< 80 yo) (23,24). With the

evolution of catheters and devices, access to the occlusion site can be easier, regardless of patients' age and vascular course (7).

IST-3 trials showed that IVT is beneficial for older people (≥ 80 yo), even those with severe stroke and with important comorbidities such hypertension, diabetes mellitus and previous stroke (25,26). Nonagenarians treated with IVT showed lower stroke-related disability at 90 days than those not treated. These observations cannot exclude a confounding effect but provide evidence that IVT should not be withheld from nonagenarians on the basis of age alone (27).

In a meta-analysis, Emberson *et al.* showed IVT benefits were similar irrespective of age or stroke severity (4). Moreover, Goyal *et al.* showed, in a meta-analysis of MT trials that included elderly patients (>80 yo), better outcomes when treated with MT (with or without IVT) compared to IVT alone (5). Malhotra *et al.* (2019) also showed that patients undergoing MT have a wider range of possible outcomes (28). In a large real-world multicenter cohort of patients stratified with the SC score (Stroke Checkerboard score) including age and stroke severity, the oldest and more severe patients had the largest benefit from MT+/-IVT (29). Systematic review and meta-analysis of published observational studies and RCTs of MT in acute ischemic stroke (AIS) demonstrated one-quarter of elderly patients (>80 yo) achieved good functional outcome at 90 days, while one-third of patients died. These findings suggest that MT+/-IVT would provide substantial benefit to a sizeable proportion of octogenarians, despite the associated comorbidities (8).

Our study had a significantly higher in-hospital mortality and lower likelihood of functional independence at discharge and at 3-6 months after IVT and/or MT than younger patients. But we found a higher proportion of AIS patients with LVO and severe stroke presentation in ≥ 80 yo group. Others factors have been identified to explain these poorer functional outcome and higher mortality rate in older patients including preexisting neuronal loss and reduced neuronal plasticity, higher rate of comorbidities and poststroke complications (eg, infections and injuries

due to falls) (30–33). Moreover, functional outcomes may be poorer than younger patients because of collateral blood supply that would be worse in elderly, resulting in earlier tissue loss (20).

Bluhmki *et al.* assessed outcomes of almost 3000 patients aged ≥ 80 yo who received IVT in RCTs or in clinical practice. Patients aged ≥ 80 yo, regardless of treatment allocation (IVT vs placebo or control), had worse functional outcomes and higher mortality rates following AIS compared with younger patients (34). Other observational studies have raised concerns about the utility of MT or IVT in the elderly because of a lower likelihood of functional independence at 90 days compared with younger patients (35,36).

3) Prognosis factors in elderly stroke patients

a. Age

In our study, an age of ≥ 80 years was associated with higher odds of poor outcome at discharge in patients undergoing IVT or MT or bridging independently. Age itself was a factor that affect clinical outcome in the elderly group (≥ 80 yo) according to Son *et al.* (7).

b. Delays

In this cohort, the time of door-to-puncture (for MT) > 120 min when patients are ≥ 80 yo is associated with higher odds of poor outcome at 3-6 months. Futhermore, many studies in literature associate earlier treatment with bigger proportional benefits (4,14). Son *et al.* shows that time to reperfusion is a factor that affect clinical outcome in the elderly group (≥ 80 yo). However, long-term clinical outcomes were significantly poorer in elderly patients. So, we can speculate that we have less time to salvage the infarcted brain in elderly patients (7).

c. Successful of recanalization

In our study, rates of successful recanalization are poorer than literature (unfortunately, we have many missing data about mTICI) and could explain poor outcome and in-hospital mortality in elderly, but patients with mTICI ≥ 2 score were significantly associated with better outcome for elderly. Although the higher TICI score is correlated to better outcome only in younger but not elderly patients in literature (9).

d. NIHSS score initial

In this cohort, higher admission NIHSS score is a significant predictor of poor outcome for the both groups. In many studies, baseline stroke severity was associated with worse outcome and a poor 90-day functional independence in elderly (≥ 80 yo) compared to younger patients (< 80 yo) (7,23). According to Sallustio *et al.*, major determinants of outcomes in this old population are initial NIHSS score and clinical improvement at 24 hours (33).

4) Pre-stroke disability in elderly

Thirty-three percent of octogenarians who present an AIS are not independent at baseline (37). A mRS of 3 may confer a relatively good quality of life for ≥ 80 yo patients and the potential shift effect of MT towards a lower mRS may be considered as a favorable outcome after MT (8).

Many studies report good functional outcome after recanalization strategies for elderly people without baseline disability and suggest the need to select patient. STRATIS (Systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke) registry relates good outcome in 43.2% of ≥ 80 yo patients without baseline disability undergoing MT. Nevertheless, this rate of good outcome decreased significantly with age, 52.4% for 80 to 84 yo patients, 38.3% for 85 to 90 yo, and 26.5% for ≥ 90 yo. An increasing of mortality was

observed, 24.5%, 27.9%, and 35.1% for the age groups respectively. 76% (748/984) of patients had a prestroke mRS score of 0 (38). We found the same evolution according to age with our results. Bluhmki and al. suggest elderly patients should be selected carefully based on their general health and baseline neurological status before IVT (34).

The definition of « good outcome » should be expanded to include return to premorbid functional status. In a study, included patients were categorized as independent premorbid (mRS 0-1) or disabled premorbid (mRS 2-4), patients with pre-existing disability may still benefit from IVT as one fourth to one third returned to the same premorbid functional level at 3 months (39).

5) Selection patient

It could be necessary to select patients with a good baseline status. Nonagenarians without pre-stroke disability, receiving IVT, showed lower disability at 90 days after AIS than patients not treated (27). In a prospective observational study, 60% of elderly patients (> 80 years), with almost all previous functional independence (mRS 0-1), regained their functional independence at 3 months (mRS 0-2) after MT (40). Many studies suggest that nonagenarians with a good pre-stroke functional status can benefit from MT for LVO (20). Nevertheless, it is difficult to know baseline status in case of emergency.

After careful imaging selection (using DWI-FLAIR mismatch selection), MT with modern devices for AIS among nonagenarians was safe and may improve neurologic recovery and functional outcome at 90 days compared with IVT alone (41).

Our study and the findings in literature highlight the need for careful patient selection for IVT and/or MT for elderly patients. The challenge remains how to identify those older patients who will not benefit from recanalization to avoid futile and potentially harmful interventions.

IVT and MT can provide benefits but magnitude of effect is carried by morbidity and mortality post-procedure (42).

Scores have been developed. In a large real-world multicenter cohort of patients, a prognosis score (the SC score, a combination of NIHSS score and patient age) was implemented and validated to sort patients who could benefit of MT into 3 different prognosis categories. The two most severe outcome categories had a marked benefit of MT and the study suggested the oldest and more severe patients had the largest benefit (29).

Campbell *et al.* showed that estimated ischemic core volume was independently associated with functional independence and functional improvement. However, this ischemic core volume did not modify the treatment benefit of MT compared with standard medical therapy for improved functional outcome. To help physicians to make MT treatment decisions and improve assessment of prognosis, combining ischemic core volume with age and expected imaging-to-reperfusion time could be useful (43).

Machine learning algorithms are currently implementing in order to help therapeutic decision including patient age. SPOT (Stroke Prognosis in Octogenarians under-going Thrombectomy) is a useful tool, based on baseline clinical and radiological data, to determine which patients to exclude from MT, and has been implemented in an online calculator for public use (44). All these artificial intelligence developments must be validated in large clinical trials.

6) Limitations

There are some limitations to this study. Firstly, the retrospective nature is one of these limitations with a selection bias: only patients hospitalized in stroke units are registered. Secondly, pre-stroke mRS and comorbidities of our patient are missing in the registry to better identify good responder to recanalization attempt. Thirdly, our registry has some important missing data (3-6 months mRS, mTICI) despite of a stable collection method carried out on a regional register in four hospitals since 2014.

CONCLUSION

Older age (≥ 80 yo) and a higher stroke severity (with higher initial NIHSS score) are poor prognostic factors in patient with AIS. Time of door-to-MT > 120 min is a poor prognostic factor in ≥ 80 yo. Poor functional outcome and mortality are higher in elderly stroke patients. The number of patients ≥ 80 yo admitted to stroke units has doubled during the last 6 years, with a 5-fold increase of recanalization procedures (n=30 in 2014; n=173 in 2019). These procedures are feasible and limit subsequent handicap in octogenarians. A careful selection of oldest patients eligible to recanalization must be considered. Moreover, stroke cases will increase in next decades notably due to aging of population. Thus, upgrade of the whole stroke network from emergency and stroke units to geriatric and rehabilitation departments is necessary in order to improve stroke cares for more patients including oldest ones.


BIBLIOGRAPHY

1. Russo T, Felzani G, Marini C. Stroke in the very old: a systematic review of studies on incidence, outcome, and resource use. *J Aging Res.* 2011;2011:108785.
2. Howard G, Goff DC. Population shifts and the future of stroke: forecasts of the future burden of stroke. *Ann N Y Acad Sci.* sept 2012;1268:14-20.
3. Béjot Y, Bailly H, Graber M, Garnier L, Laville A, Dubourget L, et al. Impact of the Ageing Population on the Burden of Stroke: The Dijon Stroke Registry. *Neuroepidemiology.* 2019;52(1-2):78-85.
4. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet Lond Engl.* 29 nov 2014;384(9958):1929-35.
5. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet Lond Engl.* 23 avr 2016;387(10029):1723-31.
6. Duffis EJ, He W, Prestigiacomo CJ, Gandhi CD. Endovascular treatment for acute ischemic stroke in octogenarians compared with younger patients: a meta-analysis. *Int J Stroke Off J Int Stroke Soc.* avr 2014;9(3):308-12.
7. Son S, Kang D-H, Hwang Y-H, Kim Y-S, Kim Y-W. Efficacy, safety, and clinical outcome of modern mechanical thrombectomy in elderly patients with acute ischemic stroke. *Acta Neurochir (Wien).* sept 2017;159(9):1663-9.
8. Hilditch CA, Nicholson P, Murad MH, Rabinstein A, Schaafsma J, Pikula A, et al. Endovascular Management of Acute Stroke in the Elderly: A Systematic Review and Meta-Analysis. *AJNR Am J Neuroradiol.* 2018;39(5):887-91.
9. Alawieh A, Starke RM, Chatterjee AR, Turk A, De Leacy R, Rai AT, et al. Outcomes of endovascular thrombectomy in the elderly: a « real-world » multicenter study. *J Neurointerventional Surg.* 2 nov 2018;
10. Papassin J, Favre-Wiki IM, Atroun T, Tahon F, Boubagra K, Rodier G, et al. Patient eligibility for thrombectomy after acute stroke: Northern French Alps database analysis. *Rev Neurol (Paris).* avr 2017;173(4):216-21.
11. MR CLEAN Investigators, Fransen PS, Beumer D, Berkhemer OA, van den Berg LA, Lingsma H, et al. MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial. *Trials.* déc 2014;15(1):343.
12. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. *N Engl J Med.* 12 mars 2015;372(11):1019-30.

13. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. *N Engl J Med*. 11 juin 2015;372(24):2296-306.
14. Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. *N Engl J Med*. 11 juin 2015;372(24):2285-95.
15. Campbell BCV, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. *N Engl J Med*. 12 mars 2015;372(11):1009-18.
16. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*. oct 2016;15(11):1138-47.
17. Liu Y, Zhao H, Zhou J, Wang Q, Chen Z, Luo N. Mild Stroke and Advanced Age Are the Major Reasons for Exclusion from Thrombolysis in Stroke Patients Admitted within 4.5 Hours. *J Stroke Cerebrovasc Dis*. juill 2014;23(6):1571-6.
18. Shamy MCF, Jaigobin CS. The complexities of acute stroke decision-making: A survey of neurologists. *Neurology*. 24 sept 2013;81(13):1130-3.
19. Gumbinger C, Reuter B, Hacke W, Sauer T, Bruder I, Diehm C, et al. Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels. *Neurology*. 24 mai 2016;86(21):1975-83.
20. Khan MA, Baird GL, Miller D, Patel A, Tsekhan S, Yaghi S, et al. Endovascular treatment of acute ischemic stroke in nonagenarians compared with younger patients in a multicenter cohort. *J NeuroInterventional Surg*. août 2017;9(8):727-31.
21. Yiin GSC, Howard DPJ, Paul NLM, Li L, Luengo-Fernandez R, Bull LM, et al. Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation-Related Embolic Vascular Events: A Population-Based Study. *Circulation*. 7 oct 2014;130(15):1236-44.
22. Ribo M, Flores A, Mansilla E, Rubiera M, Tomasello A, Coscojuela P, et al. Age-adjusted infarct volume threshold for good outcome after endovascular treatment. *J NeuroInterventional Surg*. juill 2014;6(6):418-22.
23. Sharobeam A, Cordato DJ, Manning N, Cheung A, Wenderoth J, Cappelen-Smith C. Functional Outcomes at 90 Days in Octogenarians Undergoing Thrombectomy for Acute Ischemic Stroke: A Prospective Cohort Study and Meta-Analysis. *Front Neurol*. 2019;10:254.
24. Tajima Y, Hayasaka M, Ebihara K, Kawauchi D, Suda S. Thrombectomy in Octogenarians in the Era of Stent Retriever: Is an Age Limit Necessary? *J Neuroendovascular Ther*. 2017;11(11):563-9.
25. Lindley RI, Wardlaw JM, Whiteley WN, Cohen G, Blackwell L, Murray GD, et al. Alteplase for Acute Ischemic Stroke. :12.

26. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. *Lancet Lond Engl.* 23 juin 2012;379(9834):2352-63.
27. Behrouz R, Masjuán-Vallejo J, Vera R, Willey JZ, Zedet M, Moulin S, et al. Outcomes of Nonagenarians with Acute Ischemic Stroke Treated with Intravenous Thrombolytics. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc.* janv 2018;27(1):246-56.
28. Malhotra Ajay, Wu Xiao, Payabvash Seyedmehdi, Matouk Charles C., Forman Howard P., Gandhi Dheeraj, et al. Comparative Effectiveness of Endovascular Thrombectomy in Elderly Stroke Patients. *Stroke.* 14 mars 2019;0(0):STROKEAHA.119.025031.
29. Le Bouc R, Clarençon F, Meseguer E, Lapergue B, Consoli A, Turc G, et al. Efficacy of Endovascular Therapy in Acute Ischemic Stroke Depends on Age and Clinical Severity. *Stroke.* juill 2018;49(7):1686-94.
30. Arsava EM, Rahman R, Rosand J, Lu J, Smith EE, Rost NS, et al. Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. *Neurology.* 21 avr 2009;72(16):1403-10.
31. Aurel Popa-Wagner, Stanley Thomas Carmichael, Zaal Kokaia, Christof Kessler, Lary C. Walker. The Response of the Aged Brain to Stroke: Too Much, Too Soon? *Curr Neurovasc Res.* 1 août 2007;4(3):216-27.
32. Darsalia V, Heldmann U, Lindvall O, Kokaia Z. Stroke-Induced Neurogenesis in Aged Brain. *Stroke.* août 2005;36(8):1790-5.
33. Sallustio F, Koch G, Motta C, Diomedi M, Alemseged F, D'Agostino VC, et al. Efficacy and Safety of Mechanical Thrombectomy in Older Adults with Acute Ischemic Stroke. *J Am Geriatr Soc.* août 2017;65(8):1816-20.
34. Bluhmki E, Danays T, Biegert G, Hacke W, Lees KR. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data. *Stroke [Internet].* 2 juill 2020 [cité 8 juill 2020]; Disponible sur: <https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.028396>
35. Alawieh A, Chatterjee A, Feng W, Porto G, Vargas J, Kellogg R, et al. Thrombectomy for acute ischemic stroke in the elderly: a « real world » experience. *J Neurointerventional Surg.* déc 2018;10(12):1209-17.
36. Sagnier S, Galli P, Poli M, Debruxelles S, Renou P, Olindo S, et al. The impact of intravenous thrombolysis on outcome of patients with acute ischemic stroke after 90 years old. *BMC Geriatr.* 25 août 2016;16:156.
37. Chandra RV, Leslie-Mazwi TM, Oh DC, Chaudhry ZA, Mehta BP, Rost NS, et al. Elderly Patients Are at Higher Risk for Poor Outcomes After Intra-Arterial Therapy. *Stroke.* sept 2012;43(9):2356-61.
38. Mueller-Kronast NH, Zaidat OO, Froehler MT, Jahan R, Aziz-Sultan MA, Klucznik RP, et al. Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute

- Ischemic Stroke: Primary Results of the STRATIS Registry. *Stroke*. oct 2017;48(10):2760-8.
39. Zhang W, Coote S, Frost T, Dewey HM, Choi PMC. Acute Stroke Patients With Mild-to-Moderate Pre-existing Disability Should Be Considered for Thrombolysis Treatment. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. oct 2018;27(10):2707-11.
 40. Figueiredo S, Carvalho A, Rodrigues M, Cunha A, Paredes L, Costa H, et al. Endovascular Stroke Treatment of Patients Over 80 Years Old: Cumulative Evidence from the « Real World ». *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. déc 2017;26(12):2949-53.
 41. Wu Q, Li Q, Huang C, Li Y, Wolff V, Qin X. Efficacy and Safety of Endovascular Thrombectomy for Ischemic Stroke in Nonagenarians. *Eur Neurol*. 2019;81(3-4):174-81.
 42. Young-Saver DF, Gornbein J, Starkman S, Saver JL. Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke. *Stroke*. sept 2019;50(9):2433-40.
 43. Campbell BCV, Majoie CBLM, Albers GW, Menon BK, Yassi N, Sharma G, et al. Penumbra imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. *Lancet Neurol*. janv 2019;18(1):46-55.
 44. Alawieh A, Zaraket F, Alawieh MB, Chatterjee AR, Spiotta A. Using machine learning to optimize selection of elderly patients for endovascular thrombectomy. *J Neurointerventional Surg*. 2 févr 2019;



SERMENT D'HIPPOCRATE

En présence des Maîtres de cette Faculté, de mes chers condisciples et devant l'effigie d'HIPPOCRATE,

Je promets et je jure d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la Médecine.

Je donnerai mes soins gratuitement à l'indigent et n'exigerai jamais un salaire au dessus de mon travail. Je ne participerai à aucun partage clandestin d'honoraires.

Admis dans l'intimité des maisons, mes yeux n'y verront pas ce qui s'y passe ; ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les mœurs, ni à favoriser le crime.

Je ne permettrai pas que des considérations de religion, de nation, de race, de parti ou de classe sociale viennent s'interposer entre mon devoir et mon patient.

Je garderai le respect absolu de la vie humaine.

Même sous la menace, je n'admettrai pas de faire usage de mes connaissances médicales contre les lois de l'humanité.

Respectueux et reconnaissant envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les hommes m'accordent leur estime si je suis fidèle à mes promesses.

Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque.

THÈSE SOUTENUE PAR : Manon MICHELARD

TITRE : THROMBOLYSIS AND MECHANICAL THROMBECTOMY FOR ACUTE ISCHEMIC STROKE IN OCTOGENARIAN PATIENTS: A REGIONAL OBSERVATIONAL STUDY

CONCLUSION :

Older age (≥ 80 years old) and a higher stroke severity (with higher initial NIHSS score) are poor prognostic factors in patient with AIS. Time of door-to-MT > 120 min is a poor prognostic factor in ≥ 80 y. Poor functional outcome and mortality are higher in elderly people. The number of patients ≥ 80 y admitted to stroke units has doubled during the last 6 years, with a number of recanalization procedures multiplied by 5 (n=30 in 2014; n=173 in 2019). These procedures are feasible and limit subsequent handicap in octogenarians. A careful selection of oldest patients eligible to recanalization must be considered. Moreover, stroke cases will increase in next decades notably due to aging of population. Thus, upgrade of the whole stroke network from emergency and stroke units to geriatric and rehabilitation departments is necessary in order to improve stroke cares for more patients including oldest people.

VU ET PERMIS D'IMPRIMER
Grenoble, le 18/09/2020 :

LE DOYEN



Pr. Patrice MORAND

Pour le Président
et par délégation
Le Doyen de Médecine
Pr. Patrice MORAND

LE PRÉSIDENT DE LA THÈSE

Pr. Olivier DETANTE



C-H-U Grenoble Alpes
Pôle PRéNeuro

Pr Olivier DETANTE
PU-PH

N° RPPS : 10003131397
Clinique De Neurologie
CS 10217 - 38043 Grenoble Cedex 09